Enjoy complimentary customisation on priority with our Enterprise License!
The mycoplasma testing market share is expected to increase by USD 496.87 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 11.38%.
This mycoplasma testing market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers mycoplasma testing market segmentation by product (consumables and systems) and geography (North America, Europe, Asia, and ROW). The mycoplasma testing market report also offers information on several market vendors, including Agilent Technologies Inc., ATCC , Becton Dickinson and Co., Charles River Laboratories International Inc., F. Hoffmann-La Roche Ltd., InvivoGen, Lonza Group Ltd., Merck KGaA, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. among others.
Download the Free Report Sample to Unlock the Mycoplasma Testing Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increasing focus on r&d of biopharmaceuticals is notably driving the mycoplasma testing market growth, although factors such as high cost of mycoplasma testing products may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the mycoplasma testing industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Mycoplasma Testing Market Driver
The increasing focus on the R&D of biopharmaceuticals is one of the key factors driving the growth of the global mycoplasma testing market. New class therapeutics such as cell therapy and gene therapy is gaining popularity as novel treatments for many chronic and acute diseases. Hence, many pharmaceutical companies and research institutes are focusing on the R&D of these products due to their huge market potential. The cell therapy process involves cell disassociation from the patient and developing cell culture outside the human body. The cell therapy products witness certain challenges during their manufacturing process such as issues with the sterilization of all the products and storage issues due to which at times it is immediately injected into patients. Common mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini, Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium are detected as contamination in cell cultures and the biopharmaceutical processes. Such contamination in the manufacturing process affects product quality, lowers the expression level, and reduces the production yield. Furthermore, a product developed with mycoplasma contamination triggers serious side effects in humans. Such factors will increase the market growth during the forecast period.
Key Mycoplasma Testing Market Trend
The growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies will fuel the global mycoplasma testing market growth. The leading CROs that are currently functioning in the market are IQVIA, Laboratory Corporation of America, Pharmaceutical Product Development, Syneos Health, and PRA Health Sciences. There are increasing mergers, acquisitions, and partnerships among the CROs, and between CROs and pharmaceutical and biotechnology companies. For instance, in September 2017, Laboratory Corporation of America acquired Chiltern, which helps the company to enhance its offerings, including the expansion of functional service to high-growth emerging and mid-market biopharma segments. However, traditionally clinical research was conducted in-house by the pharmaceutical and biotechnology companies. However, due to complex safety protocols, stringent government regulatory requirements, and dynamic changes in the clinical trial demographics, the companies are outsourcing clinical trials to CROs. The partnerships with CROs are important for the industries such as pharma, biotech, and Medtech to test, refine, and market the latest medical devices and pharmaceutical products. Collaboration between CROs and pharmaceutical companies can significantly contribute to increasing the R&D activities of the companies, which, in turn, will increase the demand for mycoplasma testing devices.
Key Mycoplasma Testing Market Challenge
The high cost of mycoplasma testing products is a major challenge for the global mycoplasma testing market growth. The mycoplasma testing products such as mycoplasma testing systems, assays, and frequently used consumables such as kits and reagents are associated with high costs. The cost will be further high depending on the level of features offered by the products. Integrated systems such as the BD FACSMicroCount system offer a versatile and comprehensive solution for rapid enumeration of microorganisms including product screening, sterility testing, mycoplasma testing, and probiotic count. It also measures water quality. These integrated systems with advanced features are significantly high in cost compared with the conventional mycoplasma testing systems. The cost of mycoplasma detection kits is also very high. However, these types of products can be used only for research purposes and not for diagnostic purposes. Therefore, the high cost of systems and mycoplasma detection kits is leading to the low adoption of these products by pharmaceutical companies and research organizations with limited budgets. This is limiting the growth of the global mycoplasma testing market.
This mycoplasma testing market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the global mycoplasma testing market as a part of the global life sciences tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the mycoplasma testing market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the mycoplasma testing market encompasses successful business strategies deployed by the key vendors. The mycoplasma testing market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The mycoplasma testing market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the mycoplasma testing market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the global life sciences tools and services market includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for mycoplasma testing market in North America. Market growth in this region will be slower than the growth of the market in regions.
The increasing focus on the R&D of biopharmaceuticals will facilitate the mycoplasma testing market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the prevalence of mycoplasma pneumonia in COVID-19 patients propelled the mycoplasma testing market in the region. The number of co-infection cases increased significantly in North America. This has increased the demand for mycoplasma testing, which, in turn, is expected to propel the growth of the market in the region during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The mycoplasma testing market share growth by the consumables segment will be significant during the forecast period. The consumables used for the detection of mycoplasma contamination include kits and reagents such as PCR assays, nucleic acid detection kits, staining materials, elimination kits and reagents, standards, and controls.
This report provides an accurate prediction of the contribution of all the segments to the growth of the mycoplasma testing market size and actionable market insights on post COVID-19 impact on each segment.
|
Mycoplasma Testing Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 11.38% |
|
Market growth 2021-2025 |
$ 496.87 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
10.97 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 40% |
|
Key consumer countries |
US, UK, Germany, China, and Canada |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Agilent Technologies Inc., ATCC , Becton Dickinson and Co., Charles River Laboratories International Inc., F. Hoffmann-La Roche Ltd., InvivoGen, Lonza Group Ltd., Merck KGaA, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
